In the glycolytic pathway, hexokinase (HK)-II catalyzes the first irreversible and rate-limiting step [14], but data on the prognostic role of HK-II activity after sorafenib for patients with HCC are scarce. This evidence concerns the gene HK2 and hepatocellular carcinoma.